Genotype-specific development of MEN 2 constituent components in 683 RET carriers
Endocrine-Related Cancer · 2024
DOI: 10.1530/erc-24-0038 ↗Kurz gefasst
Fachartikel in der Zeitschrift Endocrine-Related Cancer, 2024. Verfasst von Andreas Machens und 5 weiteren Autor:innen. Beteiligte Einrichtung: Medical Faculty, Department of Visceral, Vascular and Endocrine Surgery, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany. Hauptthemen laut MEDLINE: Genotype, Multiple Endocrine Neoplasia Type 2a, Multiple Endocrine Neoplasia Type 2b, Proto-Oncogene Proteins c-ret. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 30 Literaturangaben.
Abstract (Originalsprache)
The age-specific development of the three constituent components of multiple endocrine neoplasia type 2 (MEN 2) is incompletely characterized for many of the >30 causative rearranged during transfection ( RET ) mutations, which this genetic association study aimed to specify. Included in the study were 683 carriers of heterogeneous RET germline mutations: 53 carriers with 1 highest-risk mutation (codon 918); 240 carriers with 8 different high-risk mutations (codon 634); 176 carriers with 16 different intermediate-risk mutations (codon 609, 611, 618, 620, or 630); and 214 carriers with 6 different low-risk mutations (codon 768, 790, 804, or 891).There was a strong genotype-specific development of MEN 2 constituent components, with distinct age gradients from C cell disease to node negative medullary thyroid cancer (MTC), from node negative to node positive MTC, from node positive MTC to pheochromocytoma, and from pheochromocytoma to primary hyperparathyroidism. Primary hyperparathyroidism was not observed among the 53 MEN 2B patients who carried highest-risk mutations (age range: 0.5–50 years), of whom no more than 12 (23%) and 3 (6%) carriers were older than age 30 years and 35 years, respectively. The age-specific development of MTC differed significantly between the four RET risk categories, whereas the age-specific development of pheochromocytoma differed significantly only between the two strongest RET risk categories. No significant differences were noted in the development of primary hyperparathyroidism. These findings delineate age-specific disease manifestation corridors for the three constituent components of MEN 2 by RET genotype. These corridors are useful for initial risk assessment and organ-specific surveillance of newly identified RET carriers going forward.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Medical Faculty, Department of Visceral, Vascular and Endocrine Surgery, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany.
- Department of General, Visceral and Transplantation Surgery, Division of Endocrine Surgery, University of Duisburg-Essen, Essen, Germany.
- Department of Endocrinology, Diabetology and Metabolism, University of Duisburg-Essen, Essen, Germany.
ORCID-Profile: Andreas Machens, Kerstin Lorenz, Frank Weber
Zitieren
APA
Machens, A., Lorenz, K., Weber, F., Brandenburg, T., Führer-Sakel, D., & Dralle, H. (2024). Genotype-specific development of MEN 2 constituent components in 683 RET carriers. Endocrine-Related Cancer. https://doi.org/10.1530/erc-24-0038
Vancouver
Machens A, Lorenz K, Weber F, Brandenburg T, Führer-Sakel D, Dralle H. Genotype-specific development of MEN 2 constituent components in 683 RET carriers. Endocrine-Related Cancer. 2024. doi:10.1530/erc-24-0038
BibTeX
@article{Machens2024,
author = {Machens, Andreas and Lorenz, Kerstin and Weber, Frank and Brandenburg, Tim and Führer-Sakel, Dagmar and Dralle, Henning},
title = {Genotype-specific development of MEN 2 constituent components in 683 RET carriers},
journal = {Endocrine-Related Cancer},
year = {2024},
doi = {10.1530/erc-24-0038}
}
EUVIMED